Sign Up to like & get
recommendations!
0
Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24872
Abstract: Surgery followed by gemcitabine and/or a fluoropyrimidine is standard therapy for resectable PDAC. mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 Day 1, 5‐FU 2400 mg/m2 × 48 h IV, peg‐filgrastim 6 mg SQ day 3, every 14 days) has substantial…
read more here.
Keywords:
systemic therapy;
resectable pancreatic;
primary systemic;
mfolfirinox ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz247.016
Abstract: Abstract Background mFOLFIRINOX and GEM are standard chemotherapy for pts with PDAC. This single-arm phase 2 trial assessed the efficacy and safety of perioperative chemotherapy consisted of preoperative mFOLFIRINOX and postoperative GEM in pts with…
read more here.
Keywords:
pts pdac;
gem;
mfolfirinox;
rate ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.4_suppl.342
Abstract: 342 Background: mFOLFIRINOX and GEM are standard chemotherapy for metastatic and resected PDAC, respectively. This phase 2 trial assessed the efficacy and safety of perioperative chemotherapy consisted of preoperative mFOLFIRINOX and postoperative GEM in pts…
read more here.
Keywords:
pdac;
mfolfirinox;
phase trial;
surgery ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "European journal of cancer"
DOI: 10.2139/ssrn.4263813
Abstract: AIM We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). METHODS Patients with untreated LAPC were randomly assigned (1:1)…
read more here.
Keywords:
gemcitabine plus;
plus nab;
gnp;
gemcitabine ... See more keywords